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Abstract
Background: Mechanisms that underlie oscillatory transcriptional activity of nuclear receptors (NRs) are incompletely
understood. Evidence exists for rapid, cyclic recruitment of coregulatory complexes upon activation of nuclear receptors.
RIP140 is a NR coregulator that represses the transactivation of agonist-bound nuclear receptors. Previously, we showed
that RIP140 is inducible by all-trans retinoic acid (RA) and mediates limiting, negative-feedback regulation of retinoid
signaling.
Methodology and Findings: Here we report that in the continued presence of RA, long-paced oscillations of retinoic acid
receptor (RAR) activity occur with a period ranging from 24 to 35 hours. Endogenous expression of RIP140 and other RA-
target genes also oscillate in the presence of RA. Cyclic retinoid receptor transactivation is ablated by constitutive
overexpression of RIP140. Further, depletion of RIP140 disrupts cyclic expression of the RA target gene HOXA5. Evidence is
provided that RIP140 may limit RAR signaling in a selective, non-redundant manner in contrast to the classic NR
coregulators NCoR1 and SRC1 that are not RA-inducible, do not cycle, and may be partially redundant in limiting RAR
activity. Finally, evidence is provided that RIP140 can repress and be induced by other nuclear receptors in a manner that
suggests potential participation in other NR oscillations.
Conclusions and Significance: We provide evidence for novel, long-paced oscillatory retinoid receptor activity and
hypothesize that this may be paced in part, by RIP140. Oscillatory NR activity may be involved in mediating hormone
actions of physiological and pathological importance.
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Introduction
The retinoids are derivatives of vitamin A that influence
development, differentiation and homeostasis and are pharmacolog-
ically valuable in the prevention and treatment of select neoplasms
[1–3]. The biological effects of retinoids are mediated by retinoid
receptors, members of the nuclear receptor (NR) superfamily of
ligand-dependent transcription factors [4]. The functional receptor
unit for all-trans retinoic acid (RA) is the heterodimer RAR/RXR,
which binds consensus retinoic acid response elements (RAREs) in
the proximal promoters of RA target genes [4].
Positive and negative regulation of gene expression by NRs is
contingent upon coordinated interaction with coregulatory
molecules (coactivators and corepressors), which nucleate precisely
organized chromatin remodeling complexes [5]. In the absence of
ligand, interaction of the ligand-binding domain with corepressors
such as NCoR1 or NCoR2/SMRT mediates transcriptional
repression via recruitment of complexes with enzymatic histone
modifying activity [5]. Upon ligand binding, this complex
dissociates and the binding of coactivators such as SRC1/NCoA1,
SRC2/TIF2/NCoA2 or SRC3/AIB1/NCoA3 enable a tran-
scriptionally permissive chromatin configuration through histone
acetylation and other covalent modifications [5].
RIP140 is distinct from classic corepressors due to its
preferential interaction with ligand-bound NRs and is therefore
regarded as the founding member of a distinct class of coregulators
that includes LCoR and PRAME [6,7]. RIP140 directly recruits
histone deacetylases and C-terminal binding protein, a transcrip-
tional repressor, to ligand-bound NRs to repress transcription of
RA target genes [8,9].
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transcriptional target of RA and that it functionally limits retinoid
signaling, comprising a negative feedback mechanism that is
relevant to the biological activity of RA [10,11]. Depletion of
RIP140 through small interfering RNA (siRNA) sensitizes human
embryonal carcinoma cells to the antiproliferative and differenti-
ating effects of RA [11,12]. We have also demonstrated on a
genome-wide scale that RIP140 discriminates between different
classes of RA target genes [12].
It is recognized that NR signaling is temporally organized at
multiple levels [5,13]. Posttranslational modifications and prote-
olysis of NR complex components has been shown to result in
rapid cycles of NR-dependent coregulator recruitment and
transcription in the constant presence of ligand [5,13]. In this
report we provide evidence for the existence of additional, long-
paced oscillations in RAR activity. The data supports the existence
of a previously unrecognized form of RAR signaling dynamics that
may extend to other NRs and participate in the homeostasis of
hormone action.
Materials and Methods
Cell culture, siRNA and transfection protocols
NT2/D1, MCF-7, T47D, U2OS and NIH-3T3 cells were
purchased from American Type Culture Collection (Manassas,
VA). COS-1 cells were a gift from Dr. John Hwa (Dartmouth
Medical School). MCF-7 and T47D cells were cultured in
DMEM/F12 (50:50) and all other cell lines were cultured in
DMEM (Gibco).
For estrogen treatments, MCF-7 cells were cultured in phenol-
free medium beginning 24 hours before drug treatment. 17-
b2estradiol (E2) and RA were purchased from Sigma. 1,25-
dihydroxyvitamin D3 was purchased from Biomol. Dexametha-
sone and rosiglitazone were gifts from Dr. Joshua Hamilton
(Dartmouth Medical School) and Dr. Michael Sporn (Dartmouth
Medical School), respectively. RA was stored protected from light
in liquid nitrogen as a 10 mM stock solution in dimethyl sul-
foxide (DMSO). 4-[(E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-
2-naphthalenyl)-1-propenyl] benzoic acid (TTNPB, Tocris Biosci-
ence) and bexarotene (LC Laboratories) were stored away from
light at 220uC as 10 mM stock solutions in DMSO. All other
drugs were dissolved in ethanol (EtOH) and stored away from light
at 220uC. For the extended time courses of RA treatment, 1610
6
NT2/D1 cells were plated in 10 cm plates and maintained in
charcoal-absorbed sera containing media for 48 hours to deplete
endogenous NR ligands. After 48 hours, media was replaced with
serum-free media containing 2.5 mM a-amanitin (Sigma) for
2 hours. Cells were washed and DMEM containing 10%
charcoal-absorbed sera and 1 mM RA was added. RA remained
on the cells until harvest.
For siRNA experiments, custom designed siRNA duplexes for
RIP140, NCoR1 and SRC1 were purchased (Dharmacon,
Lafayette, CO). Human RIP140 siRNA is of sequence 59-
CAAACAGGAUAGCACAUUA-39 and corresponds to the
RIP140 cDNA beginning 1986 bp downstream of the ATG start
codon. Human NCoR1 siRNA is of sequence59-AAAGUC-
GUUAUCCUCCUCACU-39 and corresponds to the NCoR1
cDNA beginning 49 bp downstream of the ATG start codon.
Human SRC1 siRNA is of sequence 59-AGGAGACAGGUUA-
CUUCUG-39 and corresponds to the cDNA beginning 1467 bp
downstream of the start codon. The control was the Scrambled
siRNA of sequence 59-GCGCGCUUUGUAGGAUUCG-39 from
Dharmacon. For transient siRNA experiments, log-phase cells
were transfected with 150 nM siRNA using OligofectAMINE
(Invitrogen) as described [11,12]. Briefly, 223610
6 cells per
10 cm plate were transfected with 150 nM siRNA for 16 h. Cells
were split the following day onto 10 cm plates with charcoal-
absorbed sera media containing either 1 mM RA or DMSO. Cells
remained in this media until the time of harvest.
Conventional reporter assays
The pSG5-RIP140 expression plasmid has been described
previously [10,11]. The pCMX-PPARc expression plasmid and
the reporter constructs PPRE-tk-Luc and VDRE-tk-Luc were
kindly provided by Dr. Michael Sporn (Dartmouth Medical
School). The Ebo-RXR expression plasmid was a gift from Dr.
Ethan Dmitrovsky (Dartmouth Medical School). The pCI-mGR
expression plasmid contains the full-length murine glucocorticoid
receptor sequence and was kindly provided by Dr. Lynn Sheldon
(Dartmouth Medical School). For reporter assays, COS-1, NT2/
D1, or T47D human breast cancer cells were plated at 0.2610
6
cells per well of a 6-well plate and transfected with 2 mg total DNA
using Polyfect
TM (Qiagen) according to the manufacturer’s
instructions. Transfections were performed in triplicate for each
condition.
For the PPRE-Luc experiment, COS-1 cells were transfected
with 0.1 mg PPRE-Luc, 0.125 mg CMV-PPARc, 0.125 mg Ebo-
RXRA, 0.15 mg pSG5-RIP140, and 0.1 mg Renilla luciferase
plasmid (pRL-tk) per well. For the GRE-luc experiment, COS-1
cells were transfected with 0.1 mg GRE-Luc, 0.1 mg GR, 0.1 mg
pRL-tk, and 0.45 mg pSG5-RIP140. The dual-luciferase assay
system (Promega) was used to normalize firefly luciferase activity
against renilla luciferase activity. In all conventional reporter
transfections, total DNA was brought to 2 mg per well with salmon
sperm DNA. Media containing the transfection mixture was
removed after 16 hours and charcoal-absorbed sera media
containing 1 mM rosiglitazone, 1 mM dexamethasone, 1 mM
vitamin D3 or vehicle control (DMSO or ethanol) was added.
Cells were lysed 24 hours following drug treatment and luciferase
activity was determined. Data points represent the average of
triplicate transfections.
Real-time reporter assays
The RARE-tk-Luc reporter consists of a fusion of two RARE
sequences to a minimal herpes simplex virus-thymidine kinase
promoter and luciferase and has been used previously [10,11]. For
transient transfection real-time reporter assays, 1.5610
4 NT2/D1
cells were plated in triplicate 35 mm plates in charcoal absorbed
sera media 24 hours prior to transfection. Cells were transfected
with 1.75 mg total DNA per plate consisting of 0.75 mg RARE-tk-
Luc and 1 mg insertless pSG5 or pSG5-RIP140. For the siRNA
condition, 150 nM RIP140 siRNA was transfected with 0.75 mg
RARE-tk-Luc with otherwise identical transfection parameters as
the other three conditions. Transfections were performed using
Polyfect (Qiagen) according to the manufacturer’s directions. After
a 16 hour incubation with the transfection mixture, cells were
washed with PBS and 2 ml of Leibovitz’s L15 media (Gibco)
containing 10% charcoal-absorbed FBS, 1% penicillin/strepto-
mycin, 10 mM HEPES, 0.1 mM luciferin and 1 mMR Ao r
DMSO was added to each plate. Plates were sealed with silicone
grease and glass cover slips and immediately transferred to a
LumiCycle (Actimetrics, Wilmette, IL) for data collection as
previously described [14].
For real-time reporter assays employing U2OS and NIH-3T3
cells containing a stably integrated RARE-tk-luciferase cassette,
cells were plated to confluency in triplicate 35 mm plates in
charcoal absorbed sera media. The following day, cells were
transferred to 0.5% charcoal absorbed sera media for 2 days. For
Retinoid Receptor Oscillator
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2.5 mM a-amanitin in serum-free media for 2 hours. All cells were
then washed with PBS and 2 ml of Leibovitz’s L15 media
containing 10% charcoal-absorbed FBS, 1% penicillin/strepto-
mycin, 10 mM HEPES, 0.1 mM luciferin and 10 mMR Ao r5mM
TTNPB plus 5 mM bexarotene was added to each plate. Plates
were sealed and transferred to the LumiCycle for data collection.
The data collection interval was set for 6 collections/hour. The
LumiCycle is housed in a standard tissue culture incubator at
36uC instead of 37uC to minimize background counts. The data
was collected up to 72 to 100 hours and analyzed with the
LumiCycle Analysis software (Actimetrics). For the U2OS and
NIH-3T3 cells, the data were baseline subtracted based on a
running average as previously described [14].
The stable RARE-tk-Luc U2OS and NIH3T3 cells were
generated using a lentivirus expressing luciferase under control
of the above described RARE-tk promoter and enhancer. The
lentiviral RARE-tk-Luc plasmid was obtained by cloning the
RARE-tk portion of the RARE-tk-Luc plasmid in place of the b-
catenin response element in the Topflash lentiviral vector obtained
from Dr. Karl Willert (University of California). DNA sequencing
confirmed successful cloning.
Stable shRNA
For generation of stable RIP140 knockdown in NT2/D1 cells, a
RIP140 shRNA lentiviral construct with a sense strand sequence
of 59-GCGGAGAAGAATGAGTATGAA-39 was purchased
(Open Biosystems, clone ID TRCN0000019779). A pLKO.1-
shRNA lentiviral construct targeting eGFP of sense strand
sequence 59-TACAACAGCCACAACGTCTAT-39 was also pur-
chased (pLKO.1-eGFP, Sigma) and used as a control. Lentiviral
stocks were generated from 293T cells and psPAX2 and pMD2G
packaging and envelop vectors using standard protocols. Viral
stocks were added to NT2/D1 cells plated at 0.2610
6 cells/well
per 6 well plates. The lentiviral stock remained on the cells for
24 h. Cells were split onto 10 cm plates in selection media
containing 0.5 mg/ml puromycin. Selection continued for
48 hours, after which no viable cells remained in a mock-
transduced control plate. The puromycin-resistant cell pools were
used for experiments.
Northern hybridization, semiquantitative RT-PCR and
realtime RT-PCR
Total RNA was isolated using TriReagent (Molecular Research
Center). Northern hybridizations were performed with 5 mg RNA
as described previously [10,11] using radiolabeled 500–1100 bp
DNA fragments from RIP140, SRC1, NCoR1 or RARB. The
RIP140 probe was a 1000 bp fragment from a BglII/XhoI digest
of the pSG5-RIP140 plasmid [10,11]. The SRC1 probe was a
1071 bp fragment from a BamHI/HindIII digest of the pCR3.1-
hSRC1A construct kindly provided by Dr. Bert O’ Malley (Baylor
College of Medicine). The NCoR1 probe was a 1075 bp fragment
of the pCMX-NCoR construct provided by Dr. Ronald Evans
(The Salk Institute). For semiquantitative PCR, cDNA was
synthesized from 5 mg RNA using Superscript II reverse
transcriptase (Invitrogen), and CYP24A1 or RIP140 expression
was analyzed by PCR using Taq polymerase (Invitrogen) to cycle
numbers within the linear range as described [12]. For realtime
RT-PCR, cDNA was synthesized from 2 mg RNA using TaqMan
reverse transcription reagents (Applied Biosystems) and RIP140,
RARA, RARB, SRC1, NCoR1, and HOXA5 were amplified
from 25 ng cDNA per reaction using SYBR Green reagent
(Applied Biosystems). RIP140 transcripts containing exon 1a and
exon 1b were amplified using TaqMan primers and reagents
(Applied Biosystems). Gene expression data was normalized to
GAPDH. Primer sequences are listed in Figure S1. Data was
collected and analyzed with 7500 Fast System Sequence Detection
Software version 1.4 (Applied Biosystems).
In silico analysis of the RIP140 locus
The Evolutionarily Conserved Regions Browser (http://
ecrbrowser.dcode.org) is a graphical interface described by Loots
et al. [15]. This resource was used to search the RIP140 gene for
consensus transcription factor response elements that exhibit a
high level of evolutionary conservation. A 550 bp region of the
RIP140 ECR was amplified by genomic PCR and cloned into a
TK-luciferase construct. PCR primers were 59 TAGG-
TAAACCCTCTCTCCAGAAT and 59 ATCCTCTCCAT-
CAACTACAAAGC. DNA sequencing confirmed that the correct
sequence was cloned. The cloned sequence can be found under
the previously existing NCBI accession number, NT_011512.
Results
RAR transactivation is cyclic and sensitive to RIP140
depletion and overexpression
We sought to characterize RAR activity over an extended time
course in the constant presence of RA. To this end, NT2/D1 cells
were transiently transfected with a RA-responsive luciferase
reporter (RARE-tk-Luc), and RA-mediated RARE transactivation
was monitored in real time with a LumiCycle instrument. RA-
dependent reporter activity was monitored in biological triplicate
every 10 minutes for 76 hours following addition of RA. RA
treatment resulted in oscillatory RAR activity with an extended
period (Figure 1A and 1B). We believe this is the first
demonstration of long-timed oscillations in RAR activity in the
continued presence of RA.
Our previous studies using conventional reporter assays
established that RIP140 siRNA enhances RAR activation of
endogenous RA target genes and heterologous RARE-containing
promoters while RIP140 overexpression represses this activation
[10–12]. These studies involved only one time point (generally 24
or 48 hours). We sought to characterize whether the oscillations in
RAR activity were influenced by RIP140 by employing RIP140
siRNA or a RIP140 expression plasmid (HA-RIP140). RARE–
dependent oscillations in the constant presence of RA were
completely abolished by RIP140 overexpression driven by a
constitutive SV40 promoter that is not subject to RA regulation
(Figure 1A). The linear decline in RAR activity may reflect
accumulation of RIP140 over the course of the experiment.
RIP140 siRNA produced an overall amplification of RARE-
luciferase activity as compared to RA treatment alone. RAR
activity was robustly enhanced by RIP140 siRNA at all time points
beginning at 4 hours (Figure 1A). However, the oscillations were
slightly perturbed with a suggestion of a partially ‘‘flattened’’
response (Figure 1B). Our previous work indicated that RIP140
siRNA does not completely ablate basal or RA-induced RIP140
expression in NT2/D1 cells [11,12]. This residual RIP140
expression may account for the retention of RAR oscillation with
siRNA treatment.
Based on these data the following hypothetical model depicted
in Figure 1C is proposed. We have previously found that RA
induction of RIP140 constitutes a negative feedback mechanism
that limits and fine-tunes retinoid signaling [10–12]. The negative
feedback predicts that upon RA addition, RIP140 should
accumulate until a level sufficient to inhibit RAR activity is
attained. RIP140 expression should then decline, allowing a
Retinoid Receptor Oscillator
PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7639Figure 1. RAR-dependent transactivation is cyclic in the continued presence of RA and is sensitive to RIP140 depletion and
overexpression. A, Actively proliferating NT2/D1 cells were transiently tranfected with an RARE-tk-luciferase reporter and either a control insertless
expression plasmid (RAR-LUC + RA, RARE-LUC no RA), a RIP140 expression plasmid driven by the SV40 promoter-enhancer (RARE-LUC + RA + HA-
RIP140) or RIP140 siRNA (RARE-LUC + RA + siRNA-RIP140). Cells were then treated with RA (1 mM) or vehicle and luciferase activity was monitored in
live cells every 10 minutes for 74 hours using a LumiCyle luminometer. Each date line represents the average of three biological replicate plates. The
experiment was performed twice with similar results. B, Two of the data lines in (A), RARE-LUC + RA and RARE-LUC + RA + siRNA-RIP140 are depicted
with zoomed scaling of y-axis. Data points are represented by the error bars (S.E.M.) of the replicate plates. C, Hypothetical model representing one
interpretation of results in (A), see text for details.
doi:10.1371/journal.pone.0007639.g001
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RIP140.
A relationship between the time required to reach the initial
peak of RARE activity and RIP140 status was also evident. With
RIP140 overexpression the peak was reached most rapidly, at
5 hours (‘‘c’’ in Figure 1A), whereas with endogenous or
intermediate RIP140 levels, the peak was reached at 7 hours
(‘‘b’’ in Figure 1A). With RIP140 depletion, the peak was reached
at 13 hours (‘‘a’’ in Figure 1A).
RAR activity oscillates in U2OS cells from a stably
integrated promoter
To further examine RAR oscillatory activity, U2OS cells
containing a stably integrated RARE-tk-luciferase cassette were
utilized (Figure S2). In contrast to the NT2/D1 cells which have
decreased viability upon prolonged confluence, U2OS cells were
allowed to grow to confluence and serum-starved for 2 days prior
to ligand addition. This allowed for the assessment of time-
dependent nuclear receptor activity independent of the cell cycle.
In addition to RA, U2OS cells were also treated with a
combination of the retinoid analogs, TTNPB and bexarotene,
which are RAR and RXR selective agonists, respectively. These
ligands were chosen because they are reported to be more stable
than RA and because RIP140 has been reported to more strongly
bind to the RAR/RXR heterodimer when both RAR and RXR
are engaged with ligand [16]. In addition, a group of cells were
first treated with 2.5 mM a-amanitin for 2 hours prior to TTNPB
and bexarotene treatment in an attempt to ‘‘transcriptionally
synchronize’’ the cells [17–19]. For all treatment protocols, an
initial peak in RARE-luciferase activity was evident after
,10 hours of retinoid treatment followed by a second peak (35–
45 hours) and a third peak (,70 hours), resulting in a period
ranging from 25–35 hours (Figure S2A). There was little difference
between the RA and bexarotene/TTNPB treatments, and a-
amanitin pretreatment did not affect the results. The amplitude of
the oscillations dampened over the duration of retinoid treatment
(Figure S2A). Dampening is often seen in biological oscillators and
depends on the relative values of feedback parameters and also
results from progressive asynchronization and averaging over a cell
population [20]. No oscillations were seen when cells were treated
with the vehicle control DMSO in place of RA (data not shown).
These data indicate that RAR oscillatory activity from an
integrated reporter can be maintained in the constant presence
of RA even in cells that have left the cell cycle and are no longer
proliferating.
RAR activity oscillates in murine fibroblasts
We next examined the dynamics of RAR activation in a third
cell context, NIH-3T3 cells stably integrated with RARE-tk-
luciferase. NIH-3T3 cells were confluent and serum starved and
therefore not proliferating during the course of bexarotene and
TTNPB treatment. Luciferase activity first peaked between 8 and
12 hours, followed by two subsequent peaks at 26–32 and 60–
65 hours for a period of ranging from 25–30 hours (Figure S2B).
As seen above in U2OS cells, the amplitude of the oscillations
dampened over the duration of the retinoid treatment.
RIP140 oscillates in the constant presence of RA
The negative feedback predicts that RIP140 should cycle in the
constant presence of RA. To investigate whether RIP140 mRNA
cycles with continual RA exposure, we pretreated NT2/D1 cells
with the RNA polymerase II inhibitor, alpha-amanatin, for
2 hours and then treated the cells with RA over an extensive
57-hour time course. Treatment with alpha-amanatin is a
common strategy to synchronize NR activity and has been used
extensively to measure rapid ligand-dependent coactivator com-
plex recruitment to promoters of NR target genes [17–19]. Steady-
state RIP140 mRNA increased over the first 25 hours of RA
treatment, followed by a steady decline over the next 10 hours and
a partial recovery from 40 to 57 hours of RA treatment
(Figure 2A). Primary unspliced transcript levels also cycled with
increased amplitude (Figure 2B). The oscillations were not
observed in cells treated with alpha-amanatin alone. These
oscillations are consistent with the negative feedback model and
long 24–30 hour periodicity of RIP140 expression is consistent
with long-timed transcriptional-translational feedback. Further it is
possible that the oscillation is circadian in nature since the period
partially overlaps with a circadian period and given the known
relationship between NRs and the circadian clock apparatus [21].
Whether RIP140 would eventually decline over time due to
negative feedback of RAR activity would require longer time
points.
Figure 2. Endogenous RIP140 transcripts oscillate in the
continued presence of RA. NT2/D1 cells were pretreated with
alpha-amanitin (2.5 mM) for 2 hours and then treated with RA (1 mM) for
the indicated time points. RIP140 expression was monitored by
quantitative real-time PCR using primers in A, the processed transcript
or B, in an intron of the unspliced heteronuclear transcript. Data was
normalized to GAPDH. Trend line is the 5
th order polynomial. One
experiment of three with similar results is presented.
doi:10.1371/journal.pone.0007639.g002
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presence of RA
Cyclic RAR activation suggests that endogenous RA target
genes should also oscillate with continued RA exposure. As
depicted in Figure 3, both primary and steady state RARB
transcripts oscillate with a period of approximately 25–30 hours in
the continued presence of RA. HOXA5 expression was also cyclic
with a similar period as RARB (Figure 3). For both RARB and
HOXA5, oscillations of primary transcript levels, which are more
indicative of transcription rate, were more pronounced as
compared to steady state mRNA levels.
RIP140 depletion alters cyclic RA target gene expression
RIP140 constitutes a negative feedback mechanism to limit RA
signaling and is expressed in a cyclic fashion with continued RA
treatment. We asked whether RIP140 depletion perturbs the
oscillation of an RA target gene. The effect of RIP140 siRNA on
the cyclic expression of HOXA5 was explored. NT2/D1 cells
were transiently transfected with control or RIP140 siRNA. Cells
were subjected to a 56-hour time course of RA treatment. RNA
was harvested every 4 hours and gene expression was determined
by real-time PCR. Under these conditions RA induced a clear
oscillation in HOXA5 expression with a period approximating
30 hours in control siRNA treated cells (Figure 4). RIP140 siRNA
potentiated HOXA5 induction after RA exposure. The magnitude
of HOXA5 expression by RIP140 siRNA increased dramatically
as compared to control siRNA treated cells. At 56 hours, HOXA5
expression increased ,20-fold with RA in control siRNA cells and
,140-fold with RA in RIP140 siRNA cells (Figure 4A). Consistent
with data in Figure 3D, HOXA5 expression oscillated in control
cells (Figure 4B). The kinetics of HOXA5 expression in RIP140
siRNA cells were altered such that HOXA5 oscillations were
replaced by a continual increase in HOXA5 expression over time.
This induction had two phases, a modestly increased rate of
HOXA5 expression as compared to control cells within in the first
35 hours followed by a steep increase in the expression of HOXA5
thereafter (Figure 4A). These data suggest a potential role for
RIP140 in fine-tuning the oscillatory expression of HOXA5 in the
continued presence of RA.
RA target genes differentially respond to RIP140
depletion
Our prior work established that RIP140 siRNA enhances and
accelerates retinoid receptor transactivation, expression of RA
target genes, and RA-mediated differentiation and growth
suppression of pluripotent human embryonal carcinoma cells
Figure 3. Endogenous expression of RA target genes oscillate in the continued presence of RA. Actively proliferating NT2/D1 cells were
pretreated with alpha-amanitin (2.5 mM) for 2 hours and then treated with RA (1 mM) for the indicated time points. RARB (A, C) and HOXA5 (B, D)
expression was monitored by quantitative real-time PCR using primers in the processed transcript (A, B) or in an intron on the unspliced
heteronuclear transcript (C, D). Data was normalized to GAPDH. Trend line is the 5
th order polynomial except for B, 6
th polynomial. The experiment
was performed three times with similar results.
doi:10.1371/journal.pone.0007639.g003
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subsets of direct RA target genes differentially responded to
RIP140 depletion [12]. We wished to validate this apparent
selectivity of RIP140.
NT2/D1 cells were transduced in triplicate with a lentiviral
short hairpin RNA (shRNA) targeting RIP140, pLKO.1-RIP140,
or a control shRNA targeting GFP, pLKO.1-shGFP. RIP140
shRNA mediated substantial RIP140 depletion under both basal
and RA-treated conditions and resulted in a substantial enhance-
ment of RA dependent expression of RARB (Figure 5A). One
shRNA pool and one control pool were used to evaluate the
kinetics of RARA and RARB induction with RA. Real-time PCR
indicated enhancement of RA-dependent RARB expression but
no enhancement of RARA expression in RIP140 shRNA cells as
compared to control shRNA cells (Figure 5B–5D).
Figure 4. RIP140 depletion alters the cyclic pattern of HOXA5
expression. A, NT2/D1 cells were treated with RIP140 siRNA or control
siRNA and exposed to RA (1 mM) for the indicated time points. HOXA5
expression was measure by quantitative real-time PCR specific for
unspliced heteronuclear transcripts. B, Data in (A) for control siRNA
treated cells with zoomed scaling of y-axis. Data was normalized to
GAPDH. Trend line is the 6
th order polynomial.
doi:10.1371/journal.pone.0007639.g004
Figure 5. RAR target genes differentially respond to RIP140
depletion. A, Northern analysis depicting the effect of RIP140 shRNA
on expression of RIP140 and the known RA target gene RARB. NT2/D1
cells were treated with RIP140 shRNA lentivirus or control shRNA
lentivirus and selected in puromycin. Three individual stable pools of
RIP140 shRNA treated NT2/D1 cells and one control shRNA treated pool
were exposed to RA (1 mM) for 24 hours. The 28S ribosomal RNA served
as a loading control. B–D, Quantitative real-time PCR analysis of NT2/D1
shRNA control and NT2/D1 shRNA RIP140 cells exposed to RA (1 mM) for
the indicated time points. Data was normalized to GAPDH. Error bars
represent the range of the average of duplicate experiments for the
expression of B, RIP140; C, RARB; and D, RARA.
doi:10.1371/journal.pone.0007639.g005
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induction of RARB and HOXA5 but not RARA in NT2/D1 cells
(Figure S3 and data not shown). Further, both shRNA and siRNA
knockdown of RIP140 enhanced RA induction of RARB but not
RARA in the RA-responsive murine lung adenocarcinoma line,
ED-1 [22] (data not shown). Thus, in two different cell systems
with both siRNA and shRNA knockdown, RIP140 limits RARB
and HOXA5 but not RARA expression despite the fact that all
three genes are well-characterized, RARE-containing, direct
targets of RARs.
RIP140 distinctly regulates RAR activation as compared
to classical NR coregulators
We wished to begin to address whether RIP140 plays a distinct
role in the regulation of RA signaling as compared to classic
coregulators of nuclear receptors, the p160 family of coactivators
(SRC1, SRC2 and SRC3) and the classic corepressors (NCoR1
and NCoR2/SMRT). In contrast to RIP140 siRNA, siRNA to
NCoR1 and SRC1 failed to affect RA-dependent RARB
induction in NT2/D1 cells (Figure 6A and 6B). In addition,
knocking down RIP140, SRC1 or NCoR1 did not greatly
influence the expression of one another (Figure 6A, 6C and 6D).
While RIP140 is RA inducible and cycles in the constant presence
of RA (Figure 2), NCoR1 and SRC1 expression is not responsive
to RA and does not oscillate in the constant presence of RA
(Figure 6 and Figure S4). These data suggest that RIP140 plays a
distinct and non-redundant role in RA-signaling in NT2/D1 cells
as compared to SRC1 and NCoR1, which may share roles with
the additional known homologs SRC2, SRC3 and NCoR2.
RIP140 is a general ligand-inducible and ligand-
dependent NR corepressor
We have shown previously that a four-fold induction of RIP140
by RA occurs within 3 hours of RA treatment and de novo protein
synthesis is not required for this induction, indicating that RIP140 is
a RA target gene [10]. Gene expression profiling has identified the
upregulation of RIP140 by RA, estrogens, and vitamin D3 [23–25].
Estrogens and androgens directly induce RIP140 in MCF-7 breast
cancer cells and LNCaP prostate cancer cells, respectively [26,27].
To investigate the inducibility of RIP140 by nuclear receptor
ligands, MCF-7 cells were treated with RA, 17b-estradiol,
dexamethasone, vitamin D3, rosiglitazone or vehicle control for
24 hours and expression of RIP140 was analyzed by real-time RT-
PCR. MCF-7 cells were chosen since they are known to express the
cognate receptors for these ligands. RA caused the greatest
accumulation of RIP140 mRNA while estradiol and rosiglitazone
caused a more modest induction (Figure 7B). A slight induction of
RIP140 was also seen with vitamin D3 in MCF-7 cells (Figure 7B).
The RIP140 locus spans approximately 100 kb and consists of
one coding exon (exon 5) and several upstream non-coding exons
Figure 6. Comparison of the effects of RIP140, NCoR1 and SRC1 depletion on RA-induced RARB expression. A, Northern analysis
depicting the effect of control, RIP140, NCoR1 and SRC1 siRNA on expression of the known RA target gene RARB. NT2/D1 cells treated with the
indicated siRNA were exposed to RA (1 mM) for 24 hours. The 28S ribosomal RNA served as a loading control. Blot was hybridized to probes specific
for RARB, RIP140, NCoR1 and SRC1. Note, only RIP140 siRNA resulted in enhanced RA induction of RARB and only RIP140 is induced with RA. B–D,
Quantitative real-time PCR analysis of NT2/D1 cells treated as in (A) and assayed for expression of RARB (B), NCoR1 (C) and SRC1 (D). B and D are the
average of triplicate experiments and error bars are S.E.M. *, p,.02 with the paired, two-tailed T test. **, p,.05, with the unpaired, two-tailed T test.
(C) is the average of duplicate experiments and error bars depict the range of the two values.
doi:10.1371/journal.pone.0007639.g006
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PLoS ONE | www.plosone.org 8 October 2009 | Volume 4 | Issue 10 | e7639Figure 7. RIP140 expression is induced with RA, estrogen, dexamethasone, and rosiglitazone in MCF7 cells. A, Schematic of the RIP140
gene locus. The protein-coding region of RIP140 is contained within exon 5. A 3.5 kb highly evolutionarily conserved region (ECR) is indicated by the
arrowheads. B and C, MCF7 cells were treated with vehicle controls, DMSO or ethanol (EtOH), or RA (1 mM), estrogen (0.1 mM, E2), dexamethasone
(1 mM, Dex) or rosiglitazone (1 mM, Rosi) for 24 hours and expression of RIP140 was measured by quantitative real-time PCR with primers within exon
5 (B) or exon 1b (C). Data was normalized to GAPDH. Depicted is that average of triplicate PCR reactions of the same samples and error bars are S.D.
D, COS-1 cells were transfected with an ER-alpha expression plasmid and a control thymidine kinase (tk)-liciferase reporter (TK-Luc) or a reporter
containing a 550 bp segment of the RIP140 ECR region containing a consensus estrogen receptor response (ERE) (RIP-ECR-TK-Luc). Cells were treated
with vehicle or estrogen (0.1 mM) for 24 hours and firefly luciferase activity was determined and normalized to renilla luciferase activity. Bars are the
average of triplicate transfections and error bars are S.D. *, p,.0001 with the unpaired two-tailed T test as compared to vehicle treated RIP-ECR-TK-
Luc cells. One of two experiments with similar results.
doi:10.1371/journal.pone.0007639.g007
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alternative splicing yields multiple RIP140 transcripts [25,26,28].
In MCF-7 cells, transcripts containing 1b (Figure 7C) and 1a (data
not shown) accumulated after 24 hours of treatment with RA,
estrogen or rosiglitazone. Utilizing the Evolutionarily Conserved
Regions (ECR) browser [15], we located a 3.5 kb region between
exons 3 and 4a that is the most highly evolutionarily conserved
region in the RIP140 locus aside from the protein coding sequence
contained within exon 5 (Figure 7A). The TRANSFAC algorithm
indicated that this region contains sequences matching half or full
consensus site response elements for several NRs including ERR,
FXR, LXR, ROR, GR and also a consensus ERa/Sp1 type ER
responsive element.
We cloned a 550 bp fragment of this region into a thymidine
kinase (tk)-luciferase construct and cotransfected this plasmid along
with an ERa expression plasmid in COS-1 cells. Estrogen
treatment for 24 hours resulted in an approximate 8-fold
induction in reporter activity, supporting the presence of a
functional ERE in this region (Figure 7D). However, the construct
was not responsive to RA or dexamethasone, indicating that
functional GREs and RAREs do not exist in this region of the
RIP140 locus (data not shown).
There is growing evidence to support a role for RIP140 as a
global ligand-dependent NR corepressor [29]. We sought to
determine the effect of exogenous RIP140 on the activity of
heterologous GR- and PPARc-responsive promoters (Figure 8).
RIP140 cotransfected with GR or PPARc in COS-1 cells inhibited
GRE- and PPRE-dependent activation by dexamethasone and
rosiglitazone, respectively (Figure 8A and 8B). In addition,
induction of CYP24A1, an endogenous vitamin D3 target gene
with a well-defined VDRE, was enhanced with RIP140 siRNA in
T47D cells (Figure 8C). These results, along with the data on
RIP140 inducibility by NRs (Figure 7) supports prior studies
suggesting that RIP140 may be a general ligand-dependent and
ligand-inducible repressor of NRs [6,23–31]. These properties
suggest that RIP140 has the potential to be involved in oscillatory
transactivation of other NRs in addition to RARs.
Discussion
Oscillations are important homeostatic devices [32]. Negative
feedback drives many oscillatory events and can lend both stability
and plasticity to a biological system [32,33]. Oscillations in NR
activity may allow for control of hormone responses through
continual monitoring of ligand availability and enable NR
signaling to be poised to appropriately adjust to rapid fluctuations.
The temporal complexity of differentiation suggests that elucida-
tion of the timing of gene expression in tumor cells is important to
understand the basis of the therapeutic effects of RA. The periodic
nature of RA signaling may be an important consideration for the
more efficacious use of retinoids, for example in conjunction with
targeting coregulators like RIP140.
The past decade has revealed that NR activation is highly
dynamic. Periodic activation of NR binding, coregulator recruit-
ment, preinitiation complex assembly, and gene transcription in
the constant presence of ligand has been described for ER, GR,
and VDR [5,17–19,34–38]. These transcription cycles occur with
a short periodicity of 20–60 minutes and are mediated by
acetylation, phophorylation, proteasomal degradation and chro-
matin remodeling [5,17–19,34–38]. We provide evidence for an
additional, extended oscillation of retinoid receptor activation and
RA target gene expression in the constant presence of RA that is
long timed (24–35 hours) suggestive of a transcriptional-transla-
tional loop. Oscillatory retinoid receptor activity was evident in
Figure 8. RIP140 represses ligand dependent GR, PPARc, and
VDR activity. A, COS-1 cells were transfected with a GRE-tk-luciferase
reporter, a GR expression plasmid and an insertless expression plasmid
(empty vector) or RIP140 expressing plasmid (HA-RIP140). Cells were
treated with vehicle or dexamethasone (1 mM, Dex) for 24 hours and
firefly luciferase activity was measured and normalized to renilla
luciferase. Data are the average of triplicate transfections and error bars
are S.D. *, p,.005 with the unpaired two-tailed T test. Experiment was
repeated with similar results. B, COS-1 cells were transfected with a
PPRE-tk-luciferase reporter, PPARc and RXR expression plasmids and an
insertless expression plasmid (empty vector) or RIP140 expressing
plasmid (HA-RIP140). Cells were treated with vehicle or rosiglitazone
(1 mM, Rosi) for 24 hours and firefly luciferase activity was measured
and normalized to renilla luciferase. Data are the average of triplicate
transfections and error bars are S.D. *, p,.005 with the unpaired two-
tailed T test. One of two experiments with similar results. C, Semi-
quantitative PCR analysis of T47D cells transfected with control siRNA or
siRNA to RIP140. Cells were treated with Vitamin D3 (1 mM) for 24 hours
and expression of the VDR target gene, CYP24A1 was determined. Actin
expression was used as a control.
doi:10.1371/journal.pone.0007639.g008
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murine cell lines, with RA and RAR/RXR selective agonists,
and in cell models dependent on endogenous as well as episomal
and stably integrated promoters. In addition, the long paced cycles
were partially perturbed by overexpression and depletion of the
ligand-dependent corepressor, RIP140. Since RIP140 is acutely
inducible by RA and represses ligand bound RAR activity we
speculate that it is poised to potentially pace or fine-tune the
frequency or amplitude of these cycles.
Of note, endogenous levels of HOXA5 and to a lesser extent
RARB, tended to increase with each oscillation in the continued
presence of RA in the absence and presence of RIP140 siRNA
(Figure 3 and Figure 4). While accumulation of mRNA may be
expected to occur with each cycle, it is not clear why hnRNA
would increase with each cycle unless the rate of transcription was
also increasing with each oscillation. Further studies are necessary
to understand these findings.
It has been shown previously that short-paced oscillations of
ER, GR, and AR activity correlate with cyclic recruitment of
coregulators, (including RIP140) to the promoters of NR target
genes [5,17–19,34–38]. However, the temporal nature of
coregulator recruitment to RARs and other class II receptors that
are resident at promoters in the absence of ligand has been less
well characterized. It is currently unclear whether the long paced
oscillations we have observed are specific for RARs or coexist with
short paced cycles that have been shown for ER, GR and AR.
Although not addressed in the current study, it is conceivable that
each short-term cycle of coregulator recruitment (20–60 min)
affords the opportunity to monitor the relative ratios of
coregulators changing over a macro time scale subject to long-
term changes in environmental conditions. Thus it will be
important in the future to carefully monitor the recruitment of
coregulators in our system using techniques such as chromatin
immunoprecipitation. Interestingly, Wang et al. showed that in
contrast to ER complexes which form within minutes and recycle
hourly, complexes at AR promoters slowly form over 16 hours
and then slowly decline [39].
Although RA is required for proper maintenance of epithelial
tissues, the binary nature of RA-induced differentiation, in which
cells commit to differentiate upon a defined time interval, may not
be the ideal setting for the characterization of long-paced
oscillations of NR activity. However, the dynamic patterns we
have uncovered may be particularly relevant to other NRs that
receive constant signals such as orphan NRs (for example, ERRs),
steroid receptors that receive fairly constant hormonal stimulus
over days (ER, AR and PR), and NRs that receive signals from the
diet or intracellular metabolism (PPARs, FXRs, LXRs). It is
noteworthy the we and others have shown that RIP140 is induced
by a number of NRs including RAR, ER, PPARc, AR and ERR
and that RIP140 can in turn repress these and other NRs
(Figure 7)[6,23–31,40]. Particularly intriguing are the potential
two-way interactions between RIP140 and ERR-alpha and
PPARc, since these receptors along with RIP140 are known to
be key regulators of cellular metabolism in vivo [6,28,40–45]. It will
be of interest to discover in the future if other long-paced NR
oscillations exist and whether they integrate with rhythmic
biological processes known to involve NRs, for example, the
menstrual cycle, the circadian clock and digestive and metabolic
cycles.
Although we have provided evidence that RIP140 may
influence long-paced oscillations in NR activity, it is unclear
whether RIP140 is required for these oscillations or rather is
involved in fine-tuning their timing, frequency and amplitude.
Further, the precise timing of the oscillations differs depending on
the cell system (integrated versus episomal reporter) and assay (real
time PCR versus reporter) which may reflect differences in the
precision inherent with each technique. A more thorough
understanding of the dynamics of RIP140 expression and
processing would further support this model. RIP140 is known
to be extensively modified posttranslationally [46].
We have previously identified selectivity of RIP140 in the
regulation of RA target genes by employing microarrays on a
genome-wide scale at a 24-hour time point [12]. Consistent with
our microarray results, RARB and HOXA5 induction was
robustly potentiated by RIP140 depletion while RARA induction
was unaffected. Similar results were obtained in two different
cancer cell lines using both transient siRNA and stable shRNA.
The molecular basis of this selectivity remains unknown. The well-
characterized RAREs in the RARA and RARB promoters are
highly similar, both consist of tandem direct repeat half sites
separated by 5 bp (DR5) and only one base differs across the entire
12 bp consensus [47,48]. It is reasonable to speculate that
chromatin structure at different promoters may underlie RIP140
binding selectivity. RIP140 has been shown to be recruited to the
RARB promoter [49,50], but no studies have yet to investigate
whether RIP140 is recruited to the RARA promoter. Alternative-
ly, RIP140 may differentially affect retinoid receptor subtypes.
Selective gene regulation by RIP140 suggests that RA target genes
may undergo distinct patterns of dynamic gene expression relevant
to the growth suppressive and differentiating effects of RA.
In summary, we have shown that RAR activity and RIP140 and
RA target gene expression undergo long-paced oscillations in the
constant presence of RA. Further we provide evidence to allow us
to speculate a potential modulatory role for RIP140 in pacing and
fine-tuning these low-frequency cycles of NR activity. Tumor cell
differentiation is a highly dynamic process, and as RIP140 limits
the effectiveness of RA-mediated differentiation, further charac-
terization of the role of RIP140 in RA signaling dynamics will
afford a more accurate understanding of the beneficial therapeutic
actions of retinoids. The regulation of RIP140 by diverse
hormonal signals and its general corepression of NRs suggest that
RIP140 oscillations may be relevant to the temporal regulation of
other hormone signaling events in distinct physiologic and
pharmacologic contexts.
Supporting Information
Figure S1 Primers for PCR. Sequences are 59-39. H, human; m,
mouse; hn, heteronuclear PCR. All primers were used for
quantitative PCR with SYBR Green reagent with the exception
of those with (*) which were used for semiquantitative PCR.
Found at: doi:10.1371/journal.pone.0007639.s001 (2.09 MB TIF)
Figure S2 Stably integrated RAREs support oscillations in RAR
activity in the constant presence of RA or RAR and RXR
agonists. A, U2OS cell pools containing random, stably integrated
RARE-tk-luciferase were grown to confluence and serum starved
for 2 days prior to the addition of media containing RA (10 mM)
or the RXR pan agonist bexarotene (5 mM) + the RAR pan
agonist TTNPB (5 mM) (Bex + TTNPB). An additional group of
cells were pretreated with alpha-amanitin (2.5 mM) for 2 hours
prior to the addition of bexarotene and TTNPB (Am + Bex +
TTNPB). Upon addition of retinoids cells were placed in a
LumiCycle luminometer and luciferase activity was measured
every 10 minutes for 80 hours. Each data line is the average of
triplicate plates and data was baseline subtracted using LumiCycle
software. Inset, data in (A) with zoomed scaling. B, NIH-3T3 cell
pools containing random, stably integrated RARE-tk-luciferase
were grown to confluence and serum starved for 2 days prior to
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PLoS ONE | www.plosone.org 11 October 2009 | Volume 4 | Issue 10 | e7639the addition of bexarotene (5 mM) and TTNPB (5 mM). Cells were
transferred to a LumiCycle luminometer and luciferase activity
was measured every 10 minutes for 95 hours. Each data line
represents one of four separate replicates and data was baseline
subtracted. Inset, data in (B) with zoomed scaling. The experiment
was performed twice with similar results.
Found at: doi:10.1371/journal.pone.0007639.s002 (4.27 MB EPS)
Figure S3 RAR target genes differentially respond to RIP140
siRNA. NT2/D1 cells were treated with RIP140 siRNA or control
siRNA and treated with RA (1 mmM) for the indicated time points.
Quantitative real-time PCR analysis was performed for A, RARA
and B, HOXA5. Data was normalized to GAPDH. Error bars
represent the range of the average of duplicate experiments.
Found at: doi:10.1371/journal.pone.0007639.s003 (2.30 MB TIF)
Figure S4 NCoR1 and SRC1 do not oscillate in the continued
presence of RA. NT2/D1 cells were pretreated with alpha-
amanitin (2.5 mM) for 2 hours and then treated with RA (1 mM for
the indicated time points. NCoR1 (A) and SRC1 (B) expression
was monitored by quantitative real-time PCR. One of two
experiments with similar results is presented. Data was normalized
to GAPDH. Trend line is the 5th order polynomial.
Found at: doi:10.1371/journal.pone.0007639.s004 (2.51 MB TIF)
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